ACROBiosystems | 抗體藥物半衰期評估:新生兒 Fc 受體 (FcRn) 的關鍵作用

ACROBiosystems | 抗體藥物半衰期評估:新生兒 Fc 受體 (FcRn) 的關鍵作用

2025.04.29

Upcoming Events

|

View as Webpage

ca4eaf01-d6fb-4dfd-8bf5-01b32205c27e image
78fe8e7b-25c2-44f1-ba88-0bd67401a22e image

抗體藥物的半衰期是評估其藥代動力學特性的重要參數之一,直接影響到藥物的療效和給藥頻率。其中,抗體Fc片段與新生兒Fc受體(FcRn)的親和力是決定抗體半衰期的關鍵因素。Fc片段與FcRn(FCGRT&B2M)受體的親和力可以預測抗體的半衰期,為治療性抗體的開發提供了重要的理論依據和技術支援。

IgGs experience high serum half-life due to the protective FcRn recycling pathway. Adapted from Roopenian et al., 2007.

為評估抗體藥物的半衰期,我們提供了一系列與FcRn相關的產品和服務,包括:

  • FcRn蛋白:二聚體結構及高純度經SEC-MALS驗證;高活性經SPR/BLI驗證。
  • FcRn結合試劑盒(TR-FRET):無需洗滌步驟,可進行高通量篩選;1完成實驗。
  • FcRn穩定細胞株:穩定傳代超過20代;表達活性經FACS驗證。

Verification Data

FcRn 二聚體結構經SEC-MALS驗證

The purity of Biotinylated Canine FCGRT&B2M Heterodimer Protein, His,Avitag&Tag Free (Cat. No. FCM-C82W9) is more than 95% and the molecular weight of this protein is around 43-53 kDa verified by SEC-MALS.

FcRn與Herceptin親和力經SPR驗證

Immobilized Biotinylated Human FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCM-H82W7) on SA Chip can bind Herceptin® with an affinity constant of 0.267 μM

Request a Protocol

FcRn結合試劑盒:抗體藥物半衰期評估應用

The half-lives of these 3 monoclonal antibodies currently in clinical use generally correlate with the binding affinity to FcRn. The kit has been used to detect 3 FDA approved antibody drugs of different binding affinity to FcRn, and the IC50 trends are consistent with affinity constant from SPR as well as the actual in vivo half-life published.

Request a Free Sample

Awards & Certifications

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!